Immunome Target of Unusually High Options Trading (NASDAQ:IMNM)

by · The Cerbat Gem

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) saw some unusual options trading activity on Monday. Traders bought 2,906 call options on the company. This is an increase of 347% compared to the typical daily volume of 650 call options.

Institutional Investors Weigh In On Immunome

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Immunome by 43.4% in the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock worth $28,987,000 after acquiring an additional 1,303,753 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Immunome by 34.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 614,387 shares of the company’s stock worth $4,135,000 after purchasing an additional 157,135 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Immunome by 38.2% in the first quarter. Deutsche Bank AG now owns 63,682 shares of the company’s stock worth $429,000 after purchasing an additional 17,607 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Immunome by 67.5% in the first quarter. Swiss National Bank now owns 128,000 shares of the company’s stock valued at $861,000 after purchasing an additional 51,600 shares in the last quarter. Finally, Invesco Ltd. boosted its position in shares of Immunome by 6.4% during the first quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock valued at $191,000 after buying an additional 1,718 shares during the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Stock Performance

Immunome stock traded up $5.19 during mid-day trading on Monday, reaching $24.76. The stock had a trading volume of 5,874,155 shares, compared to its average volume of 1,149,020. The firm has a market capitalization of $2.27 billion, a PE ratio of -8.37 and a beta of 2.17. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $25.30. The stock’s 50-day simple moving average is $16.94 and its 200-day simple moving average is $12.29.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, research analysts forecast that Immunome will post -2.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Craig Hallum assumed coverage on shares of Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price target on the stock. The Goldman Sachs Group started coverage on Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Truist Financial began coverage on Immunome in a research note on Monday, December 1st. They set a “buy” rating and a $36.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. Finally, Guggenheim reiterated a “buy” rating and issued a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.00.

View Our Latest Stock Analysis on Immunome

Immunome Company Profile

(Get Free Report)

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

Further Reading